Healthcare Industry News: LINZESS
News Release - March 10, 2017
Tris Pharma Appoints New Chief Commercial Officer for Brand Business
MONMOUTH JUNCTION, N.J., March 10, 2017 -- (Healthcare Sales & Marketing Network) -- Tris Pharma, Inc. (Tris) a specialty pharmaceutical company with a robust portfolio of approved NDAs and late-stage pipeline of innovative technology-based product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), today announced that it has appointed Paul Rogers as its new Chief Commercial Officer to lead Tris' brand business.Paul has worked for both large and small pharma companies, and brings more than 25 years of industry experience – first in clinical research and then in commercial roles. He has led commercialization of well-known, successful brands such as Nexium, Crestor, Vyvanse and most recently LINZESS.
"Paul has a unique perspective having launched and led several successful brands in different therapeutics categories," said Ketan Mehta, President and Chief Executive Officer of Tris. "His track record of creating and developing high-performing, dedicated teams and bringing results in the most challenging situations is what Tris needs today."
"I am excited to join the Tris Team. The entrepreneurial spirit and can do attitude is infectious," said Paul Rogers. "I look forward to contributing to the success of the lead brand Dyanavel XR, as well as the pipeline of innovative product candidates."
Sharon Clarke, who until recently served as Chief Commercial Officer, will transition to a newly created position of Senior Vice President, Corporate Development of Pediatric Business. In this role, Sharon will focus on enhancing Tris' pediatric portfolio and pipeline. Mehta added, "Sharon's extensive knowledge of strategic development within the allergy/respiratory, pain, CNS and ophthalmology markets makes her an ideal individual to lead Tris in the continued development of our Pediatric Business."
About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of innovative, technologies-driven products. Tris has pioneered the delivery of controlled release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D, manufacturing and commercial facilities are located in Monmouth Junction, New Jersey, U.S.A.
For more information, please visit www.trispharma.com
Source: Tris Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
